Clinical trials: Myeloid Leukemia, Chronic
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
The main goal of this study is to evaluate the stability of molecular response (major and deep molecular response( MMR and DMR)) in patients with chronic myeloid leukemia (CML) with stable DMR after two-stage dose reduction phase…
- Conditions
- Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia
- Trial name
- READIT (NCT04578847)
- Testing
- Imatinib, Nilotinib, Dasatinib
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- National Research Center for Hematology, Russia
Leukemia
Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease
Although allogeneic stem cell transplantation is curative in CML, evidence of the BCR-ABL oncogene at low levels is still found in long-term follow-up of survivors.
- Trial name
- NCT00819143
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Collecting and Storing Blood Samples From Patients With Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00900120
- Sponsor
- University of Medicine and Dentistry of New Jersey
CML-CP; Mutation;Suboptimal Response or Failure in TKI
Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib
Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML) and is the current standard of care in the treatment of patients with newly diagnosed CML.
- Trial name
- NCT04681820
- Testing
- Flumatinib, Nilotinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia - Chronic Phase
Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines
The goal of this observational study is to evaluate the efficacy and tolerability of asciminib in real-life in patients with chronic myeloid leukemia treated in second or subsequent lines.
- Trial name
- ASCIRLI (NCT07640750)
- Volunteers
- 98 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
The main goal of the study is the assessment of duration of major molecular response (MMR) or better at 12 and 36 months after stopping tyrosine kinase inhibitors (TKI) therapy a second or third time in patients with at least…
- Trial name
- NAUT (NCT02917720)
- Testing
- TKI discontinuation, nilotinib
- Where
- 15 sites in Germany, Netherlands
- Volunteers
- 75 people
- Sponsor
- European LeukemiaNet
Leukemia, Myeloid, Acute, Refractory AML
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with…
- Conditions
- Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2
- Trial name
- TUSCANY (NCT03850574)
- Testing
- Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 240 people
- Sponsor
- Aptose Biosciences Inc.
Acute Biphenotypic Leukemia, Acute Leukemia
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment.
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hairy Cell Leukemia
- Trial name
- NCT03739606
- Testing
- Anti-CD123/CD3 Monoclonal Antibody MGD006
- Sponsor
- City of Hope Medical Center
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
- Conditions
- Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03844048
- Testing
- Venetoclax
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- AbbVie
Chronic Myeloid Leukemia
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib
Imatinib (IM) is first-line treatment for patients with newly diagnosed CML in chronic phase. The drug is associated with high rates of cytogenetic responses with minimal toxicity in approximately 80% of patients.
- Trial name
- NCT01215487
- Testing
- Stem Cell and Mutational Assay
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- University of British Columbia
Myeloid Leukemia, Chronic
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia
The first purpose of this study is to evaluate the persistence of the complete molecular remission in patients with Chronic Myeloid Leukemia after stopping imatinib treatment (determine by Reverse Transcription real-time…
- Trial name
- STIM (NCT00478985)
- Testing
- Imatinib ending
- Where
- 24 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Leukemia
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have…
- Trial name
- NCT00005618
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
MDS
A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response
Treatment of patients with WHO defined IPSS int 2 and high risk MDS , AML with 20-30% marrow blasts and CMML type 2, after failure of azacitidine or decitabine exposure for at least 6 courses, or relapse after initial response.
- Trial name
- NCT02197676
- Testing
- SGI-110 administration
- Where
- 27 sites in France
- Volunteers
- 56 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
This phase II trial studies how well topotecan hydrochloride and carboplatin with or without veliparib work in treating patients with myeloproliferative disorders that have spread to other places in the body and usually cannot be…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT03289910
- Testing
- Carboplatin, Topotecan, Topotecan Hydrochloride
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myelogenous Leukemia, Hematologic Malignancies
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory…
- Trial name
- NCT00660920
- Testing
- Ponatinib
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Ariad Pharmaceuticals
Graft Versus Host Disease, Leukemia
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
RATIONALE: Giving chemotherapy, such as clofarabine, melphalan, and thiotepa, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00423514
- Testing
- filgrastim, clofarabine, melphalan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myeloid, Chronic Phase
Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)
This study investigated the safety and efficacy of 400mg Versus 800mg imatinib in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints.
- Trial name
- TOPS (NCT00124748)
- Testing
- Imatinib mesylate
- Where
- 75 sites in United States, Argentina and 4 more
- Volunteers
- 476 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myelodysplastic Syndromes
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
RATIONALE: Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Lenalidomide may also stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00352001
- Testing
- azacitidine, lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Mikkael Sekeres MD
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT04060277
- Testing
- Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.